ETFs with ONXX as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|4.2%||PowerShares Dynamic Biotech &Genome (PBE)||+0.79 (3.49%)|
|3.03%||iShares NASDAQ Biotechnology Index Fund (IBB)||+41.15 (29.59%)|
|2.45%||SPDR Series Trust SPDR S&P Biotech ETF (XBI)||+19.72 (22.10%)|
|2.35%||First Trust Health Care AlphaDEX (FXH)||+3.86 (11.79%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
We are a biopharmaceutical company dedicated to developing and commercializing innovative therapies that target the molecular mechanisms that cause cancer. By applying our expertise to develop and commercialize therapies designed to exploit the genetic and molecular differences between cancer cells and normal cells, we have built two franchise platforms — one in kinase inhibition and one in proteasome inhibition. In our kinase inhibitor franchise, our lead product, Nexavar® (sorafenib) tablets, is approved in multiple countries for unresectable liver cancer and advanced kidney cancer. With our development and marketing partner Bayer HealthCare Pharmaceuticals Inc., or Bayer, we share equally in the profits and losses of Nexavar worldwide, except Japan. ... More ...